Bortezomib for Injection Sdz 3.5 mg (Bortezomib (Bortezomib Mannitol Boronic Ester) POWDER FOR SOLUTION) 3.5 MG

Bortezomib for Injection SDZ 3.5 mg is a powder for solution used in intravenous therapy. This medication is designed to support specific therapeutic needs, often related to cancer treatment. Learn more about its uses and effects.

Strength

3.5 MG

Manufacturer / TM Owner

SANDOZ CANADA INCORPORATED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bortezomib for Injection SDZ 3.5 mg is primarily used in the management of certain types of cancer. It works by interfering with the growth and spread of cancer cells. Patients often wonder, 'What is Bortezomib used for?' This medication is typically prescribed for conditions like multiple myeloma and mantle cell lymphoma, aiming to provide relief and improve quality of life.

Side Effects

Common effects of Bortezomib for Injection SDZ 3.5 mg may include fatigue, nausea, and peripheral neuropathy. Some users also report diarrhea or constipation. These effects can vary widely depending on individual health factors and the specific condition being treated.

Precautions & Warnings

Handling Bortezomib for Injection SDZ 3.5 mg requires careful attention to dosage and administration guidelines. It is important to follow the instructions provided by a healthcare professional to minimize potential risks. Always store the medication properly and use it as directed.

Avoid Interactions

Bortezomib for Injection SDZ 3.5 mg may interact with other medications, including those that affect the liver or immune system. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also impact the effectiveness of this medication.

Frequently Asked Questions

Bortezomib is primarily used in the treatment of certain types of cancer, such as multiple myeloma and mantle cell lymphoma.

Bortezomib is administered intravenously as a powder for solution.

Common side effects may include fatigue, nausea, peripheral neuropathy, diarrhea, and constipation.

Bortezomib may interact with other medications, so it is important to consult a healthcare provider before combining treatments.

Bortezomib should be stored according to the instructions provided by the manufacturer to maintain its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.